secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124626
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics reports Q3 net product sales of $32.8M; narrows FY2024 guidance to positive Adj EBITDA
--------------------------------------------------------------------------------

- Q3 acute care franchise net product sales $7.4M (+57% YoY); oncology franchise $25.4M (-5% YoY).
- YTD Adjusted EBITDA positive at $1.4M; FY2024 Adj EBITDA guidance narrowed to $2M-$5M (from $(10)-$3M).
- ZYNRELEF VAN approved Sep 24, on track for Q4 launch; CMS final rule includes ZYNRELEF for separate payment ($2,267.26 limit) through at least 2027.
- Cash and equivalents $70.9M at Sep 30, 2024 vs $80.4M at Dec 31, 2023.
- Total net product sales for first 9 months 2024: $103.5M vs $92.8M in prior year period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/0000950170-24-124626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer